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Background: Data on the prevalence of contraindications and conditions requiring precaution for the administration of P2Y12 inhibitors in real-
life patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are scarce.
methods: We performed detailed recording of contraindications and conditions requiring precaution for clopidogrel, prasugrel and ticagrelor in ACS 
patients undergoing PCI in the context of a prospective multi-centre, observational study of antiplatelet treatment patterns in ACS patients subjected 
to PCI in Greece.
results: From January to August 2012, 875 patients were included in analysis, 82.3% men, with a mean age of 62.5±18.8 years, 23.3% 
diabetics, 53.5% current smokers and 50.4% admitted with ST elevation myocardial infarction. In total 16.7%, 42.7% and 35.5% of patients had 
at least one absolute contraindication or special condition requiring precaution for clopidogrel, prasugrel and ticagrelor respectively. Conditions, 
common among the 3 agents,requiring precaution were: recent injury or surgery (0.5%), recent gastrointestinal bleeding (0.9%), home-medication 
increasing bleeding risk (3.4%), renal failure (3.1%) and concomitant conditions increasing bleeding risk (5.6%). Contraindications/conditions 
requiring precaution only for prasugrel were prior stroke (18.6%), age ≥75 years (16.1%) and weight < 60Kg (3.1%) while only for ticagrelor were 
severe chronic obstructive pulmonary disease (4.2%), hyperuricaemia/prior gout crisis (6.3%) and increased risk of bradycardia (0.7%). In total 
116(13.3%) patients had at least 1 contraindication or condition requiring precaution for the administration of all 3 agents.
conclusions: In a real-world ACS population treated with PCI, there is a relative high rate of contraindications or specific conditions requiring 
precaution for the administration of P2Y12 inhibitors, especially for prasugrel and ticagrelor.
